Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidancehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance


Pfizer Inc. (NYSE:PFE) today announced that it has amended its supply agreement with the U.S. government for Paxlovid, the first oral antiviral pill approved by the U.S. Food and Drug

Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR): https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (“Aurinia” or the “Company”), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, today

U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)


Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg
Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1


Almirall S.A. (BME:ALM), a global biopharmaceutical company focused on medical dermatology, today announced the presentation of new data on lebrikizumab through 18 abstracts, including two oral

Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
ICON Secures Upgraded Credit Rating from S&P Global Ratings: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
ICON Secures Upgraded Credit Rating from S&P Global Ratings


ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that S&P Global Ratings (S&P) upgraded ICON to an investment grade credit rating

Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program


Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program. The

U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancerhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer


Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adult patients with

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Poxel Announces its Participation at Upcoming Investor Conferences: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Announces its Participation at Upcoming Investor Conferences


Regulatory News:



POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic

EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023
Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management
Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management
Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management
Charles River Laboratories Achieves 90% Renewable Electricity Globally, Announces Progress on Environmental Goals: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Achieves 90% Renewable Electricity Globally, Announces Progress on Environmental Goals


Charles River Laboratories International, Inc. (NYSE: CRL) today announced that, while working toward previously announced environmental goals, the Company has achieved 90 percent renewable

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg
Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis


Almirall S.A. (BME:ALM), a global biopharmaceutical company focused on medical dermatology, unveiled new data at the European Association of Dermatology and Venereology Congress 2023 that

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Transgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab): https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab)


Regulatory News:



Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq

EQS-News: Formycon Ranibizumab Biosimilar FYB201/CIMERLI®1 achieved 25% market share2 in the United States
EQS-News: Formycon Ranibizumab Biosimilar FYB201/CIMERLI®1 achieved 25% market share2 in the United States
EQS-News: Formycon Ranibizumab Biosimilar FYB201/CIMERLI®1 achieved 25% market share2 in the United States
Cosmo announces submission of Winlevi® to the European Medicines Agency (EMA)
Cosmo announces submission of Winlevi® to the European Medicines Agency (EMA)
Cosmo announces submission of Winlevi® to the European Medicines Agency (EMA)
Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone
Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone
Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone
Newron TRS Study 6 Months’ Results: Evenamide Substantially Improves Patients to an Extent That They No Longer Meet Protocol Entry Criteria: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
Newron TRS Study 6 Months’ Results: Evenamide Substantially Improves Patients to an Extent That They No Longer Meet Protocol Entry Criteria


Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral

Savara Announces New Employment Inducement Grant: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara Announces New Employment Inducement Grant


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees.



On October 3

Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseaseshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases


Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2023 held in Boston from October 11-15, 2023. Data from 45 abstracts will highlight the